Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIDOVEN: Venetoclax + 3+7 + Midostaurin in FLT3-mutated AML
NCT07726576Phase 2Not yet recruiting
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in acute myeloid leukemia (AML), sponsored by Centre Hospitalier Universitaire de Bordeaux. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07726576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07726576.